drugset / Trial / NCT07159009
A Study of GB261 in Systemic Sclerosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of GB261 in patients with SSc.
Timeline
- Start
- 2025-09-04
- Primary completion
- 2026-12-01
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GB261 | Protein / enzyme biologic | — | — |